AI assistant
DBV Technologies — Regulatory Filings 2022
Jun 16, 2022
1248_iss_2022-06-16_8ff8e74f-940e-4738-993d-2f62bf8b5f58.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Montrouge, France, June 16, 2022
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York.
A webcast of the presentation will be available on the Investors & Media section of the Company's website: https://www.dbv-technologies.com/investor-relations/
A replay ofthepresentationwill alsobeavailableonDBVTechnologies'websiteafter the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies' food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak DBV Technologies +1 857-529-2363 [email protected]
Media Contact
Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]